Wang Jianping, Xue Hengchuan, Zhu Zonghai, Gao Jie, Zhao Mengmeng, Ma Zhenkai
Department of Thoracic Surgery, People's Hospital of Yangzhong City, Yangzhong, Jiangsu 212200, P.R. China.
Oncol Lett. 2020 Oct;20(4):30. doi: 10.3892/ol.2020.11891. Epub 2020 Jul 17.
The present study aimed to investigate the expression of serum exosomal miR-23b-3p in non-small cell lung cancer (NSCLC) and to determine its diagnostic efficacy for NSCLC. From October, 2017 to October, 2019, 80 patients with NSCLC, 60 patients with pneumonia and 30 healthy subjects undergoing physical examination were enrolled at the People's Hospital of Yangzhong City. Serum samples were collected from the 3 groups of patients. The expression of miR-23b-3p in exosomes was detected by RT-qPCR. The Chi-squared test was used to analyze the expression level of miR-23b-3p in exosomes, and the patients with NSCLC were divided into 2 groups according to the expression level. The association between the patient clinicopathological parameters and receiver operating characteristic (ROC) curves was used to evaluate the diagnostic efficacy of serum exosomal miR-23b-3p in NSCLC. The expression level of serum exosomal miR-23b-3p in the patients with NSCLC was significantly higher than that in patients with pneumonia (t=10.332, P<0.001) and healthy subjects (t=12.810, P<0.001); serum exosomal miR-23b-3p was significantly associated with tumor size, depth of invasion, liver metastasis and TNM stage (P<0.05). The area under the curve (AUC) for miR-23b-3p was 0.915 (95% CI, 0.84-0.92), the optimal relative expression of miR-23b-3p was 3.46, the sensitivity of diagnosis was 87.4%, and the specificity was 93.8%, all higher than that of carcinoembryonic antigen (CEA). The ROC of NSCLC was 0.645 (95% CI, 0.641-0.772) and for Cyfra21-1 it was 0.745 (95% CI, 0.701-0.812). Compared with the patients with pneumonia and the healthy subjects, the patients with NSCLC exhibited a higher level of serum exosomal miR-23b-3p. On the whole, these findings indicate that miR-23b-3p has a higher clinical diagnostic efficacy and may thus be a potential biomarker for the early diagnosis of NSCLC.
本研究旨在探讨血清外泌体miR-23b-3p在非小细胞肺癌（NSCLC）中的表达情况，并确定其对NSCLC的诊断效能。2017年10月至2019年10月，扬中市人民医院纳入了80例NSCLC患者、60例肺炎患者和30例接受体检的健康受试者。收集3组患者的血清样本。采用RT-qPCR检测外泌体中miR-23b-3p的表达。采用卡方检验分析外泌体中miR-23b-3p的表达水平，并根据表达水平将NSCLC患者分为2组。通过患者临床病理参数与受试者工作特征（ROC）曲线的关联来评估血清外泌体miR-23b-3p对NSCLC的诊断效能。NSCLC患者血清外泌体miR-23b-3p的表达水平显著高于肺炎患者（t=10.332，P<0.001）和健康受试者（t=12.810，P<0.001）；血清外泌体miR-23b-3p与肿瘤大小、浸润深度、肝转移和TNM分期显著相关（P<0.05）。miR-23b-3p的曲线下面积（AUC）为0.915（95%CI，0.84-0.92），miR-23b-3p的最佳相对表达量为3.46，诊断敏感性为87.4%，特异性为93.8%，均高于癌胚抗原（CEA）。NSCLC的ROC为0.645（95%CI，0.641-0.772），细胞角蛋白19片段（Cyfra21-1）的ROC为0.745（95%CI，0.701-0.812）。与肺炎患者和健康受试者相比，NSCLC患者血清外泌体miR-23b-3p水平更高。总体而言，这些发现表明miR-23b-3p具有较高的临床诊断效能，可能是NSCLC早期诊断的潜在生物标志物。
